Cargando…

Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety

INTRODUCTION: Although use of contraception was pre-specified during cladribine clinical trials for multiple sclerosis, some pregnancies did occur. OBJECTIVE: This analysis reports on pregnancy outcomes in the cladribine clinical development program. METHODS: Pregnancy outcomes in female patients (d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giovannoni, Gavin, Galazka, Andrew, Schick, Regina, Leist, Thomas, Comi, Giancarlo, Montalban, Xavier, Damian, Doris, Dangond, Fernando, Cook, Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305061/ https://www.ncbi.nlm.nih.gov/pubmed/32447743 http://dx.doi.org/10.1007/s40264-020-00948-x

Ejemplares similares

Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers
por: Stuve, Olaf, et al.
Publicado: (2019)

Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing–remitting multiple sclerosis: the CLARITY Extension study
por: Comi, Giancarlo, et al.
Publicado: (2018)

Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study
por: Giovannoni, Gavin, et al.
Publicado: (2018)

The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020)

Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies
por: De Stefano, Nicola, et al.
Publicado: (2021)

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study
por: Montalban, Xavier, et al.
Publicado: (2018)

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis
por: Oh, Jiwon, et al.
Publicado: (2021)

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies
por: Giovannoni, Gavin, et al.
Publicado: (2021)

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study
por: Freedman, Mark S, et al.
Publicado: (2017)

Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets
por: Giovannoni, Gavin, et al.
Publicado: (2021)

COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update
por: Jack, Dominic, et al.
Publicado: (2021)

Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update
por: Jack, Dominic, et al.
Publicado: (2021)

Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study
por: Freedman, Mark S, et al.
Publicado: (2021)

Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
por: De Stefano, Nicola, et al.
Publicado: (2017)

Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
por: Giovannoni, Gavin, et al.
Publicado: (2022)

The Multiple Sclerosis Care Unit
por: Soelberg Sorensen, Per, et al.
Publicado: (2018)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

Effects of cladribine tablets on heart rate, atrio‐ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis
por: Hermann, Robert, et al.
Publicado: (2019)

Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
por: Alvarez‐Gonzalez, Cesar, et al.
Publicado: (2017)

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells
por: Ceronie, Bryan, et al.
Publicado: (2018)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment
por: Kalatskaya, Irina, et al.
Publicado: (2023)

Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis
por: Terranova, Nadia, et al.
Publicado: (2018)

Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets
por: Jack, Dominic, et al.
Publicado: (2020)

Immunomodulatory Effects Associated with Cladribine Treatment
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?
por: Mateo-Casas, M., et al.
Publicado: (2020)

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
por: Mao, Zhifeng, et al.
Publicado: (2018)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis
por: Baker, David, et al.
Publicado: (2022)

Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis
por: Allen-Philbey, Kimberley, et al.
Publicado: (2023)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine
por: Hermann, Robert, et al.
Publicado: (2021)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
por: Clavelou, Pierre, et al.
Publicado: (2023)

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
por: Brochet, Bruno, et al.
Publicado: (2023)

Cladribine as a Potential Object of Nucleoside Transporter-Based Drug Interactions
por: Hermann, Robert, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fgvl9cvq1a6tmun1q84im0k3l6